title: Dual contrast enhancement of both T1- and T2-weighted sequences using ultrasmall superparamagnetic iron oxide.
abstract: BMS 180549 (previously AMI-227), an ultrasmall superparamagnetic iron particulate agent, was investigated to determine its utility as a contrast agent on T1-weighted, as well as T2-weighted sequences, as a function of route of administration, (intravenous versus selective arterial) and concentration. Twelve farm pigs were divided into three groups of four each by route of administration (intravenous, selective superior mesenteric, or selective hepatic arterial injection). 10 mumol/kg and 20 mumol/kg dosages were given and evaluated both immediately after and 20-24 hr after contrast infusion, using both spin-echo and gradient-echo T1 and T2-weighted sequences. Significant postcontrast liver and spleen enhancement was noted at both concentrations, regardless of route of administration on both T1- and T2-weighted sequences. The earliest postcontrast T1-weighted sequence obtained during the 1-3 min interval following IV administration of high dose (20 mumol/kg) contrast demonstrated an average of +42.8% liver and +249.0% spleen enhancement; 24 hr later this decreased to 0 and 7.2%, respectively. The earliest postcontrast T2-weighted sequence obtained during the 8-17 min interval post high-dose IV contrast showed an average of -75.8% decrease in liver and -28.7% decrease in spleen signal intensity; 24 hr later the magnitude of these changes diminished to -33.1% and +2.5%, respectively. No significant difference was noted in liver or spleen enhancement, regardless of route of contrast administration (intravenous versus intraarterial).
authors.affiliation: Emory University School of Medicine, Department of Radiology, Atlanta, GA 30322.
authors.forename: W C
authors.initials: WC
authors.lastname: Small
authors.forename: R C
authors.initials: RC
authors.lastname: Nelson
authors.forename: M E
authors.initials: ME
authors.lastname: Bernardino
mesh_terms: D000818:Animals; D003287:Contrast Media / Q000008:administration & dosage*; D003911:Dextrans; D052203:Ferrosoferric Oxide; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D007501:Iron / Q000008:administration & dosage*; D008099:Liver / Q000033:anatomy & histology; D008279:Magnetic Resonance Imaging / Q000379:methods*; D058185:Magnetite Nanoparticles; D010087:Oxides / Q000008:administration & dosage*; D013154:Spleen / Q000033:anatomy & histology; D013552:Swine; D013997:Time Factors
chemical_list: D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; C097921:ferumoxtran-10; D007501:Iron; D052203:Ferrosoferric Oxide